Clinical Trials Logo

Crohn's Disease clinical trials

View clinical trials related to Crohn's Disease.

Filter by:

NCT ID: NCT03884439 Not yet recruiting - Ulcerative Colitis Clinical Trials

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Start date: March 31, 2019
Study type: Observational

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.

NCT ID: NCT03870334 Not yet recruiting - Crohn's Disease Clinical Trials

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Start date: March 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 induction compared to placebo in subjects with moderate to severe CD. Approximately 70 sites will participate from Europe and the United States (US).

NCT ID: NCT03854305 Recruiting - Crohn's Disease Clinical Trials

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease

Start date: March 20, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of oral PRV-6527 in the treatment of moderately to severely active Crohn's disease

NCT ID: NCT03850509 Not yet recruiting - Crohn's Disease Clinical Trials

Efficacy and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation

Start date: June 4, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is the effects, safety and how OPS-2071(150, 300, or 600 mg twice a day [BID]) is as an add-on therapy in Crohn's disease who show symptoms of active inflammation despite being on ongoing treatment.

NCT ID: NCT03833596 Recruiting - Crohn's Disease Clinical Trials

Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)

Start date: October 25, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the effect of Exclusive Enteral Nutrition (EEN) in addition to different regimes of corticosteroid (CS) therapy (Prednisone) compared to CS alone in adults participants with active Crohn's Disease, on symptoms and inflammation after 6 weeks of treatment. Participants will be randomized to three treatment arms: standard CS, standard CS with EEN, short course CS with EEN. Participants will be assessed through questionnaires for gut symptoms, quality of life, mood changes and dietary patterns and potential mechanisms will be investigated by collecting stool samples for characterization of gut bacterial profiles, collection of blood to determine inflammatory markers and evaluation of gut motility before and after treatment. The investigators hypothesize that six weeks of EEN with CS will be more effective than CS alone in inducing clinical remission in patients with active CD, as well as leading to beneficial changes in the composition and/or metabolic activity of the intestinal microbiota, gastrointestinal transit and inflammatory burden. Furthermore, six weeks of EEN in addition to a short course of CS will have similar efficacy than EEN with standard course of CS and reduced number of adverse events.

NCT ID: NCT03759288 Recruiting - Crohn's Disease Clinical Trials

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Start date: December 7, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy

NCT ID: NCT03757065 Not yet recruiting - Multiple Sclerosis Clinical Trials

Cell Surface Marker Expression in Autoimmune Diseases

Start date: January 7, 2019
Study type: Observational

This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's disease, (f) ulcerative colitis and (g) inflammatory myositis.

NCT ID: NCT03733314 Recruiting - Crohn's Disease Clinical Trials

A Study of E6011 in Participants With Active Crohn's Disease

Start date: November 27, 2018
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to examine the efficacy and safety of E6011 after administration by means of double-blind placebo-controlled trial.

NCT ID: NCT03729674 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

Start date: November 26, 2018
Study type: Observational [Patient Registry]

In Canada and worldwide there is a need for updated independent real-world comparative effectiveness and safety data related to biologic drugs including biosimilar drugs. Biosimilar drugs hold potential to improve access to needed therapies at reduced cost enabling savings to be reallocated to other needs. However updated real-world evidence on comparative effectiveness and safety of biosimilar drugs is lacking. Investigators aim to demonstrate feasibility of creating network of clinical cohorts and other resources to provide real-world information on use of biosimilar drugs in Canada. The core revolves around clinical datasets but investigators will complement with other data sources. Investigators will review data from National Prescription Drug Utilization Information System database that contains prescription claims-level data collected from publicly financed drug benefit programs in different provinces to conduct an environmental scan of the use of biosimilars and respective legacy drugs and other anti-Tumor Necrosis Factor agents covered by provincial drug plans from 2014-2017. Initial analysis will help to confirm that use of biosimilars is lower than corresponding legacy drugs. Biologic drugs are relatively new and expensive drugs; biosimilar medicines are similar to original biologic drugs but cost less. If patients receive biosimilar drugs rather than originator biologics healthcare systems may be able to save money. Those savings can be used for other health care needs to benefit more Canadians. However investigators do not have detailed information on safety and effectiveness of these biosimilar drugs. The aim of study is to compare safety and effectiveness of biosimilar drugs to originator biologic drugs. Investigators will study patients with inflammatory rheumatic diseases (RA and AS) and Inflammatory Bowel Disease (CD and UC) and across Canada on these drugs. Primary focus is on patients without history of biologic drug use but investigators will also study patients switching to biosimilar drug from an originator biologic drug. Investigators will measure how long patients stay on treatment, if patients require new treatment, if the patients' disease control improves and occurrence of side effects such as infection that could be related to these drugs.

NCT ID: NCT03710486 Recruiting - Ulcerative Colitis Clinical Trials

A Study to Observe Vedolizumab Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants

Start date: February 19, 2019
Study type: Observational

The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and second line) vedolizumab versus other biologics at least 6 months post-treatment initiation.